Vote en Assemblée Générale

28 May 2025 08:00 CEST

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Vote at the General Assembly

Paris, France, and Manchester, UK - May 28, 2025 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, will hold its Ordinary and Extraordinary General Meeting ("Meeting") at 13:00 CEST/12:00 BST on Thursday, June 19, 2025 at the Hilton Hotel, Paris Charles de Gaulle Airport, 8 Rue de Rome, 93290 Tremblay-en-France, France. As usual, the Assembly presents both ordinary and extraordinary resolutions.

All documents are available online at www.novacyt.com/investors.

Shareholders are strongly encouraged to cast their votes in advance, in accordance with the instructions set out in the notice of the Meeting.

In accordance with the provisions of the French Commercial Code, in order for the AGM and the EGM to reach a quorum on first notice, shareholders representing at least 20% of the share capital and voting rights, for ordinary resolutions, and 25% of the share capital and voting rights, for extraordinary resolutions, must be present, represented or have voted in advance under the conditions described below.

Shareholders have the opportunity to vote before the Meeting by doing the following:

• Download a copy of the proxy voting form from the www.novacyt.com/investors website, complete it and return it together with proof of their participation in the capital in the form of a share certificate (attestation), either by post to the following address: CIC Services Assemblées Générales, 6 avenue de Provence 75452 Paris Cedex 09, or by e-mail to the following address: serviceproxy@cic.fr or investor.relations@novacyt.com, no later than 15 June 2025 inclusive.

• Vote online on the Votaccess portal at the following address: http://www.actionnaire.cic-marketsolutions.eu, if their securities listed on Euronext Growth are held with one of the following banks: CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will be accessible from 28 May 2025 to 18 June 2025 at 2pm BST/3pm CEST.

• Vote online through an authorized broker, agent, bank, or intermediary. Many intermediaries in the UK, such as Hargreaves Lansdown, now use the Broadridge ProxyVote online voting portal.

Only shareholders who can prove that the shares have been registered in their name or in that of the intermediary registered on their behalf on the second business day prior to the Meeting, i.e. June 16, 2025 at midnight, Paris time (12am CEST/11pm BST), will be able to participate in the Meeting: 

· either in the registered share accounts held by the company,

· or in bearer securities accounts held by the authorised intermediary.

Shareholders wishing to attend the Annual Meeting in person may:

• For shareholders whose shares are registered: present themselves on the day of the Meeting, with an identity document

• For shareholders whose shares are bearer: ask the authorised intermediary managing their securities account to send them proof of participation or a letter of representation, attesting that they hold Novacyt shares.

Shareholders may also request an admission card in advance (a) from CIC Services, by mail at the following address: CIC Services Assemblées Générales, 6 avenue de Provence 75452 Paris Cedex 09, or by email at the following address: serviceproxy@cic.fr; or (b) on the secure VOTACCESS platform accessible via the https://www.actionnaire.cic-marketsolutions.eu website.

Shareholders who have already voted (by proxy, through their broker, proxy, bank, authorized intermediary, Votaccess portal or Broadridge ProxyVote) will be permitted to attend the Meeting but will not be able to vote twice.

Following the Meeting, a recording of the Meeting will be posted on the Company's website at www.novacyt.com/investors.

Contacts

About the Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company that offers a broad portfolio of integrated technologies and services, primarily focused on genomic medicine. The company develops, manufactures, and markets a range of molecular tests and instruments providing workflows and services that enable seamless end-to-end solutions from sample to result across multiple industries, including human health, animal health, and the environment.

The company is divided into three business segments:

Novacyt's headquarters are located in Le Vésinet, France. The Company has offices in Manchester, UK, Singapore, the United States and Canada, and has operations in more than 65 countries. The company is listed on the AIM market of the London Stock Exchange ("NCYT") and on the Euronext Growth market of the Paris Stock Exchange ("ALNOV").

For more information, please visit our website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com

91952_FR0010397232.pdf